Aquila Capital logo

Aquila Capital

Europe, Hamburg, Germany, Hamburg

Description

Aquila Capital is provides institutional investors worldwide with alternative investments solutions in real assets and private markets.

Investor Profile

Aquila Capital has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (50%)
  • Series C (50%)

Country Focus

  • United States (50%)
  • India (50%)

Industry Focus

  • Biotechnology
  • Clinical Trials
  • Therapeutics
  • Automotive
  • E-commerce
  • Information Services
  • Information Technology
  • Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Aquila Capital frequently co-invest with?

Axis Bank
Asia, Maharashtra, India, Mumbai
Co-Investments: 1
CapitalG
North America, California, United States, San Francisco
Co-Investments: 1
HDFC Bank
Asia, Maharashtra, India, Mumbai
Co-Investments: 1
Hillhouse Investment
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
RNT Associates
Asia, Maharashtra, India, Mumbai
Co-Investments: 1
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 1
MPM Capital
North America, Massachusetts, United States, Boston
Co-Investments: 1
Dentsu
North America, New York, United States, New York
Co-Investments: 1
Peak XV Partners
Asia, Karnataka, India, Bengaluru
Co-Investments: 1
Burrage Capital
North America, Massachusetts, United States, Boston
Co-Investments: 1

Which angels does Aquila Capital often collaborate with?

RT
North America, Texas, United States, Houston
Shared Deals: 1

What are some of recent deals done by Aquila Capital?

CarDekho

Gurgaon, Haryana, India

CarDekho is a car search platform working to digitize the auto ecosystem.

AutomotiveE-CommerceInformation ServicesInformation TechnologySoftware
Series CJan 3, 2019
Amount Raised: $110,000,000
argenx

Boston, Massachusetts, United States

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityJun 3, 2016
Amount Raised: $34,098,310